Nuformix plc (LON:NFX – Get Free Report) rose 8.7% during mid-day trading on Wednesday . The stock traded as high as GBX 0.09 ($0.00) and last traded at GBX 0.09 ($0.00). Approximately 3,331,248 shares changed hands during mid-day trading, a decline of 96% from the average daily volume of 74,219,031 shares. The stock had previously closed at GBX 0.08 ($0.00).
Nuformix Stock Up 18.5 %
The business’s 50-day moving average is GBX 0.07 and its 200-day moving average is GBX 0.09. The company has a market capitalization of £1.18 million, a price-to-earnings ratio of -2.92 and a beta of 1.22.
Nuformix (LON:NFX – Get Free Report) last released its earnings results on Wednesday, January 29th. The company reported GBX (0.46) (($0.01)) EPS for the quarter.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Further Reading
- Five stocks we like better than Nuformix
- Investing In Automotive Stocks
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
- Retail Stocks Investing, Explained
- Gold’s Ascent: Can Miners and ETFs Take Investors to $3,000?
- Consumer Staples Stocks, Explained
- Medtronic’s Expansion Gains Momentum—Time for a Market Shift?
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
